Development and validation a nomogram for predicting the risk of severe COVID-19: A multi-center study in Sichuan, China.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
03
2020
accepted:
30
04
2020
entrez:
19
5
2020
pubmed:
19
5
2020
medline:
22
5
2020
Statut:
epublish
Résumé
Since December 2019, coronavirus disease 2019 (COVID-19) emerged in Wuhan and spread across the globe. The objective of this study is to build and validate a practical nomogram for estimating the risk of severe COVID-19. A cohort of 366 patients with laboratory-confirmed COVID-19 was used to develop a prediction model using data collected from 47 locations in Sichuan province from January 2020 to February 2020. The primary outcome was the development of severe COVID-19 during hospitalization. The least absolute shrinkage and selection operator (LASSO) regression model was used to reduce data size and select relevant features. Multivariable logistic regression analysis was applied to build a prediction model incorporating the selected features. The performance of the nomogram regarding the C-index, calibration, discrimination, and clinical usefulness was assessed. Internal validation was assessed by bootstrapping. The median age of the cohort was 43 years. Severe patients were older than mild patients by a median of 6 years. Fever, cough, and dyspnea were more common in severe patients. The individualized prediction nomogram included seven predictors: body temperature at admission, cough, dyspnea, hypertension, cardiovascular disease, chronic liver disease, and chronic kidney disease. The model had good discrimination with an area under the curve of 0.862, C-index of 0.863 (95% confidence interval, 0.801-0.925), and good calibration. A high C-index value of 0.839 was reached in the interval validation. Decision curve analysis showed that the prediction nomogram was clinically useful. We established an early warning model incorporating clinical characteristics that could be quickly obtained on admission. This model can be used to help predict severe COVID-19 and identify patients at risk of developing severe disease.
Sections du résumé
BACKGROUND
Since December 2019, coronavirus disease 2019 (COVID-19) emerged in Wuhan and spread across the globe. The objective of this study is to build and validate a practical nomogram for estimating the risk of severe COVID-19.
METHODS
A cohort of 366 patients with laboratory-confirmed COVID-19 was used to develop a prediction model using data collected from 47 locations in Sichuan province from January 2020 to February 2020. The primary outcome was the development of severe COVID-19 during hospitalization. The least absolute shrinkage and selection operator (LASSO) regression model was used to reduce data size and select relevant features. Multivariable logistic regression analysis was applied to build a prediction model incorporating the selected features. The performance of the nomogram regarding the C-index, calibration, discrimination, and clinical usefulness was assessed. Internal validation was assessed by bootstrapping.
RESULTS
The median age of the cohort was 43 years. Severe patients were older than mild patients by a median of 6 years. Fever, cough, and dyspnea were more common in severe patients. The individualized prediction nomogram included seven predictors: body temperature at admission, cough, dyspnea, hypertension, cardiovascular disease, chronic liver disease, and chronic kidney disease. The model had good discrimination with an area under the curve of 0.862, C-index of 0.863 (95% confidence interval, 0.801-0.925), and good calibration. A high C-index value of 0.839 was reached in the interval validation. Decision curve analysis showed that the prediction nomogram was clinically useful.
CONCLUSION
We established an early warning model incorporating clinical characteristics that could be quickly obtained on admission. This model can be used to help predict severe COVID-19 and identify patients at risk of developing severe disease.
Identifiants
pubmed: 32421703
doi: 10.1371/journal.pone.0233328
pii: PONE-D-20-08771
pmc: PMC7233581
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0233328Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Am J Respir Crit Care Med. 2001 Jun;163(7):1730-54
pubmed: 11401897
JAMA. 2017 Oct 10;318(14):1377-1384
pubmed: 29049590
Nature. 2002 Jun 20;417(6891):822-8
pubmed: 12075344
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1022-1023
pubmed: 32060619
BMJ. 2012 Sep 04;345:e5875
pubmed: 22951554
Am Rev Respir Dis. 1993 Nov;148(5):1418-26
pubmed: 8239186
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Stat Med. 2007 Dec 30;26(30):5512-28
pubmed: 18058845
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Bus Contin Emer Plan. 2020 Jan 1;13(4):298-312
pubmed: 32438951
J Infect. 2020 Apr;80(4):388-393
pubmed: 32112884
JAMA. 2020 Mar 17;323(11):1092-1093
pubmed: 32031568
Front Microbiol. 2019 Dec 03;10:2752
pubmed: 31849894
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
Int J Surg. 2018 Dec;60:266-272
pubmed: 30496867
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
BMJ Open Respir Res. 2018 Jan 30;5(1):e000240
pubmed: 29468073
J Med Virol. 2020 Jun;92(6):612-617
pubmed: 32108351
J Clin Oncol. 2008 Mar 10;26(8):1364-70
pubmed: 18323559
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
N Engl J Med. 2020 Feb 20;382(8):692-694
pubmed: 31978293
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
BMC Pulm Med. 2017 May 2;17(1):78
pubmed: 28464807
Int J Infect Dis. 2020 Feb;91:264-266
pubmed: 31953166
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143